ERBB2 and neoplasm: It detects combinatorial abnormalities in protein biomarkers (e.g., CK, EpCAM, VIM, HER2, and PD‐L1) and chromosomal aneuploidy (e.g., chromosome 8 polysomy) tailored to tumor profiles [65, 66].